Cagrilintide and Retatrutide are both Metabolic peptides, but they're studied for different things. In short, Cagrilintide is a long-acting amylin analog studied for appetite and weight, often with semaglutide, while Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
Cagrilintide vs Retatrutide at a glance
| Cagrilintide | Retatrutide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | A long-acting amylin analog studied for appetite and weight, often with semaglutide. | An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. |
| Researched for | Appetite regulation, Weight management, Satiety | Weight management, Blood sugar regulation, Metabolic health |
| Research status | Clinical trials — investigational. | Phase III clinical trials — investigational, not yet approved. |
| Typically stacked with | Semaglutide | — |
| Key consideration | Investigational and not approved as a standalone product. Medical supervision advised. | Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision. |
How does Cagrilintide work?
Cagrilintide is a long-acting analog of amylin, a hormone co-released with insulin that promotes satiety and slows gastric emptying. It is studied on its own and combined with semaglutide (as CagriSema) for appetite and weight management.
How does Retatrutide work?
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
Cagrilintide vs Retatrutide: how to choose
Choosing between Cagrilintide and Retatrutide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. Cagrilintide is most associated with Appetite regulation and Weight management, while Retatrutide leans toward Weight management and Blood sugar regulation. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. Cagrilintide is a long-acting amylin analog studied for appetite and weight, often with semaglutide; Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. They're most researched for Appetite regulation, Weight management (Cagrilintide) and Weight management, Blood sugar regulation (Retatrutide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
Cagrilintide: Clinical trials — investigational. Retatrutide: Phase III clinical trials — investigational, not yet approved.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.